Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


21.08.2017

1 Am J Hematol
3 Ann Hematol
7 Blood
1 Br J Cancer
3 Br J Haematol
5 Cancer
1 Eur J Haematol
1 J Pediatr Hematol Oncol
4 Leukemia
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. GOLDBERG SL, Cortes J, Gambacorti-Passerini C, Hehlmann R, et al
    First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
    Am J Hematol. 2017 Aug 17. doi: 10.1002/ajh.24887.
    PubMed     Text format     Abstract available


    Ann Hematol

  2. JAWHAR M, Naumann N, Schwaab J, Baurmann H, et al
    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
    Ann Hematol. 2017;96:1463-1470.
    PubMed     Text format     Abstract available

  3. HAROUN F, Solola SA, Nassereddine S, Tabbara I, et al
    PD-1 signaling and inhibition in AML and MDS.
    Ann Hematol. 2017;96:1441-1448.
    PubMed     Text format     Abstract available

  4. BRAULKE F, Schulz X, Germing U, Schuler E, et al
    Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Ann Hematol. 2017;96:887-894.
    PubMed     Text format     Abstract available


    Blood

  5. AL SAYED MF, Ruckstuhl CA, Hilmenyuk T, Claus C, et al
    CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
    Blood. 2017;130:297-309.
    PubMed     Text format     Abstract available

  6. AGATHANGGELOU A, Smith E, Davies NJ, Kwok M, et al
    USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Blood. 2017;130:156-166.
    PubMed     Text format     Abstract available

  7. GOMES-SILVA D, Srinivasan M, Sharma S, Lee CM, et al
    CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Blood. 2017;130:285-296.
    PubMed     Text format     Abstract available

  8. YOSHIMI A, Balasis ME, Vedder A, Feldman K, et al
    Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Blood. 2017;130:397-407.
    PubMed     Text format     Abstract available

  9. GODLEY LA, Shimamura A
    Genetic predisposition to hematologic malignancies: management and surveillance.
    Blood. 2017;130:424-432.
    PubMed     Text format     Abstract available

  10. KARJALAINEN R, Pemovska T, Popa M, Liu M, et al
    JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Blood. 2017;130:789-802.
    PubMed     Text format     Abstract available

  11. DURHAM BH, Getta B, Dietrich S, Taylor J, et al
    Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
    Blood. 2017 Aug 11. pii: blood-2017-01-765107. doi: 10.1182/blood-2017-01-765107
    PubMed     Text format     Abstract available


    Br J Cancer

  12. FORERO-CASTRO M, Robledo C, Benito R, Bodega-Mayor I, et al
    Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
    Br J Cancer. 2017;117:256-265.
    PubMed     Text format     Abstract available


    Br J Haematol

  13. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal.
    Br J Haematol. 2017;177:991-999.
    PubMed     Text format     Abstract available

  14. CORREA DE ARAUJO KOURY L, Ganser A, Berliner N, Rego EM, et al
    Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.
    Br J Haematol. 2017;177:979-983.
    PubMed     Text format     Abstract available

  15. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
    Br J Haematol. 2017;177:1000-1007.
    PubMed     Text format     Abstract available


    Cancer

  16. LIN CJ, Vader JM, Slade M, DiPersio JF, et al
    Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
    Cancer. 2017;123:1800-1809.
    PubMed     Text format     Abstract available

  17. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Text format     Abstract available

  18. STAHL M, Zeidan AM
    Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Cancer. 2017;123:1703-1713.
    PubMed     Text format     Abstract available

  19. LEHMANN V, Tuinman MA, Keim MC, Winning AM, et al
    Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
    Cancer. 2017;123:1869-1876.
    PubMed     Text format     Abstract available

  20. EL-JAWAHRI A, Chen YB, Brazauskas R, He N, et al
    Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    Cancer. 2017 Jan 19. doi: 10.1002/cncr.30546.
    PubMed     Text format     Abstract available


    Eur J Haematol

  21. PAPROCKA M, Bielawska-Pohl A, Rossowska J, Krawczenko A, et al
    MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Eur J Haematol. 2017 Aug 14. doi: 10.1111/ejh.12938.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  22. MCNEW BR, Darbro BW, Ma D, Gordon DJ, et al
    Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma.
    J Pediatr Hematol Oncol. 2017 Aug 14. doi: 10.1097/MPH.0000000000000924.
    PubMed     Text format     Abstract available


    Leukemia

  23. KUMAR B, Garcia M, Weng L, Jung X, et al
    Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
    Leukemia. 2017 Aug 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  24. ARTESI M, Marcais A, Durkin K, Rosewick N, et al
    Monitoring molecular response in adult t-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.
    Leukemia. 2017 Aug 16. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  25. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
    Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  26. HEHLMANN R, Lauseker M, Saussele S, Pfirrmann M, et al
    Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    PLoS One

  27. ARCHER NP, Perez-Andreu V, Stoltze U, Scheurer ME, et al
    Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility.
    PLoS One. 2017;12:e0180488.
    PubMed     Text format     Abstract available

  28. MARCEL V, Catez F, Berger CM, Perrial E, et al
    Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.
    PLoS One. 2017;12:e0170160.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: